Please assess the completion status of the following clinical trial:

Trial Title: A Trial to Evaluate the Safety, Efficacy, and Tolerability of Brexpiprazole in Treating Agitation Associated With Dementia of the Alzheimer's Type

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Participants with a diagnosis of probable Alzheimer's disease.~* Participants with a diagnosis of agitation~* Participants with a MMSE score of 5 to 22, inclusive, at screening and baseline visits.~* Participants with a previous MRI or CT scan of the brain, that was performed after the onset of symptoms of dementia, with findings consistent with a diagnosis of Alzheimer's disease.~* Participants who are residing at their current location for at least 28 days before screening and are expected to remain at the same location for the duration of the trial.~* Institutionalized participants with an identified caregiver who has sufficient contact (minimum of 2 hours per day for 4 days per week) to describe the participant's symptoms and has direct observation of the participant's behavior. Non-institutionalized participants may not be living alone and must have an identified caregiver who has sufficient contact (minimum of 2 hours per day for 4 days per week) to describe the participant's symptoms and has direct observation of the participant's behavior.~* Participants with onset of symptoms of agitation at least 2 weeks prior to screening visit.~* Participants will and able to discontinue all prohibited concomitant medications to meet protocol required washouts prior to and during the trial period.~Exclusion Criteria:~* Participants with dementia or other memory impairment not due to Alzheimer's disease.~* Participants with a history of stroke, well-documented transient ischemic attack, or pulmonary or cerebral embolism.~* Participants who had an insufficient response, based on the investigator's judgment, to 2 or more previous antipsychotic medications.~* Participants who have been diagnosed with an Axis I disorder.~* Participants who currently have clinically significant neurological, hepatic, renal, metabolic, hematological, immunological, cardiovascular, pulmonary, gastrointestinal, or psychiatric disorders.~* Participants with uncontrolled hypertension or symptomatic hypotension, or orthostatic hypotension.~* Participants with diabetes mellitus (insulin-dependent and non-insulin-dependent) may be eligible for the trial if their condition is stable and well-controlled.

- Gender: ALL
- Minimum Age: 55 Years
- Maximum Age: 90 Years
- Healthy Volunteers: f

Study Arms:
- Brexpiprazole 2 mg (Type: EXPERIMENTAL): Participants followed a titration schedule, to gradually increase their dose from 0.5 milligrams per day (mg/day) in the starting to 2 mg/day from Day 15. Participants continued to receive brexpiprazole 2 milligrams (mg), once daily until Week 12.
- Brexpiprazole 3 mg (Type: EXPERIMENTAL): Participants followed a titration schedule, to gradually increase their dose from 0.5 mg/day in the starting to 3 mg/day from Day 29. Participants continued to receive brexpiprazole 3 mg, once daily until Week 12.
- Placebo (Type: PLACEBO_COMPARATOR): Participants received matching placebo, once daily for 12 weeks.

Based on this trial design, predict the completion outcome and termination type (if applicable).